Chemours reports Q2 EPS 58c, consensus 46c

Reports Q2 revenue $1.6B, consensus $1.57B. “Our results surpassed our expectations for the quarter, with improved performance across each of our three businesses driven by strong demand for Opteon, volume growth in TT, and favorable pricing in APM. We also made significant progress against Pathway to Thrive through our Strengthening the Long Term pillar, reaching a settlement to comprehensively resolve all statewide environmental claims, including those related to PFAS in New Jersey,” said Denise Dignam, Chemours (CC) President and CEO. “We also remain equally focused on the other key pillars in our strategy with an emphasis on Operational Excellence, considering recent operational headwinds as we work to drive an improved operating model to reduce business disruptions going forward.”